| Biomarker ID | 1511 |
| PMID | 25151013 |
| Year | 2015 |
| Biomarker | Prostate Health Index (PHI) |
| Biomarker Basis | Concentration Based (ng/mL) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs No Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 531 men with PSA levels between 3 and 15 ng/ml undergoing first-time prostate biopsy were chosen. 271 had Prostate cancer and 231 had Benign Biopsy |
| Senstivity | NA |
| Specificity | NA |
| AUC | 70.4 (95% CI: 66.1–74.8) |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | NA |
| Clinical | No |
| Remarks | PHI = [(p2PSA / fPSA) / √tPSA] |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |